Department of Dermatology, University Francois Rabelais Tours CHRU Tours, Tours, France.
Acta Derm Venereol. 2011 Mar;91(2):169-71. doi: 10.2340/00015555-1025.
Treatment of hidradenitis suppurativa (HS) is often unsatisfactory. The efficacy of infliximab for treatment of the disease has been suggested. The main objective of this study was to evaluate the efficacy and side-effects of infliximab in the treatment of moderate to severe HS, resistant to local and systemic treatments. The secondary objective was to determine whether inflammation blood test results were changed. A retrospective monocentric study of all the patients seen consecutively for HS and treated with infliximab was performed. A median of six intravenous infusions (range 3-19) were performed. The end-points were self-improvement of HS (globally and in terms of pain, seeping and quality of life). The condition of six of seven patients improved (by nearly 50%) and none was aggravated. Adverse effects occurred in two patients; eczematous eruption in one case and cervical abscess in another case. We found no significant changes in inflammatory blood marker values. In conclusion, infliximab therapy was shown to be efficient and well tolerated in six of seven patients with HS resistant to previous therapy in our series. This was in agreement with pre-existing literature showing that 52 of 60 patients (87%) were improved after infliximab therapy.
治疗化脓性汗腺炎（HS）常常不尽人意。英夫利昔单抗治疗该病的疗效已被提出。本研究的主要目的是评估英夫利昔单抗治疗局部和全身治疗抵抗的中重度 HS 的疗效和副作用。次要目的是确定炎症血液检查结果是否发生变化。对所有因化脓性汗腺炎而连续就诊并接受英夫利昔单抗治疗的患者进行了回顾性单中心研究。中位数为 6 次静脉输注（范围 3-19）。终点是 HS 的自我改善（整体和疼痛、渗出和生活质量方面）。7 名患者中有 6 名（近 50%）病情改善，无一例加重。两名患者出现不良反应；一例为湿疹样皮疹，另一例为颈脓肿。我们发现炎症血液标志物值没有显著变化。总之，在我们的系列中，7 名对既往治疗抵抗的化脓性汗腺炎患者中，有 6 名患者对英夫利昔单抗治疗有效且耐受良好。这与先前的文献一致，表明 60 名患者中有 52 名（87%）在接受英夫利昔单抗治疗后得到改善。
